Zhejiang Huahai Pharmaceutical Co., Ltd.

Equities

600521

CNE000001DL5

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-28 pm EDT 5-day change 1st Jan Change
17.17 CNY +0.41% Intraday chart for Zhejiang Huahai Pharmaceutical Co., Ltd. -2.05% +17.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution MT
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21% MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection MT
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. CI
Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets MT
Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 14, 2023 has closed with 7,023,600 shares, representing 0.48% for CNY 99.99 million. CI
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit MT
Shyndec Pharmaceutical's Unit Gets Nod to Register Empagliflozin Tablets MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. CI
Zhejiang Huahai Pharmaceutical Gets US FDA's Nod for Pemetrexed Disodium for Injection MT
Correction: Huahai Pharmaceutical Gets Nod to Amend Specifications for Irbesartan Tablets MT
Huahai Pharmaceutical Gets Nod to Amend Spefication for Irbesartan Tablets MT
Zhejiang Huahai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Huahai Pharma Selling 1.4 Billion Yuan Shares For Capacity Expansion MT
Huahai Pharma to Repurchase Up to 100 Million Yuan Shares MT
Huahai Pharma Unit Gets FDA Nod to Trial Cancer Drug MT
Zhejiang Huahai Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Huahai Pharma Registers Drug for Prostate Treatment MT
Ningbo Menovo Pharma Registers Blood Pressure Drug MT
Huahai Pharmaceutical Gets US FDA's Nod for Dicyclomine Hydrochloride Capsules MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chart Zhejiang Huahai Pharmaceutical Co., Ltd.
More charts
ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
17.17 CNY
Average target price
18.5 CNY
Spread / Average Target
+7.75%
Consensus
  1. Stock Market
  2. Equities
  3. 600521 Stock
  4. News Zhejiang Huahai Pharmaceutical Co., Ltd.
  5. Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit